Cepheid is the leading innovator in the field of molecular diagnostics. The Company is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use systems and tests. By automating highly complex procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular testing that can dramatically enhance the management of infectious diseases and cancer.
As an organization, Cepheid’s mission is “to enable molecular diagnostic testing of any patient specimen on a centralized or disseminated basis, thereby enabling medical providers to identify and treat diseases early, increasing opportunities to improve patients’ survival and quality of life.” Last month, Cepheid made strides toward achieving this mission when it received clearance from the FDA for Xpert CarbaR, which is the first FD-Aapproved test for use in detecting carbapanem resistance of multidrug-resistant superbugs. This new test could be instrumental in progress in the fight against antimicrobial resistance.
We are very excited to announce that Cepheid will be a gold sponsor at the 2016 edition of the World Anti-Microbial Resistance Congress USA! For the chance to interact with Cepheid and learn from their tireless work to tackle antimicrobial resistance, attend the World Anti-Microbial Resistance Congress, held September 8-9 in Washington, DC.